Maya Martinez-Davis joined GSK in September 2019 to lead the $20B+ pharmaceuticals and vaccines businesses in the US and Puerto Rico as president of US Pharmaceuticals.

She brings nearly two decades in the industry leading people, energizing teams, and delivering on strategy to expand markets in the US, Latin America, and beyond. Her strategic insights cover many therapeutic areas with deep expertise in oncology and specialty treatments. Since joining GSK, Maya has played a pivotal role in the company’s launch of multiple oncology medicines. Looking ahead, her leadership will be vital as the company prepares to launch various specialty medicines and vaccines, develop new respiratory and immuno-inflammation medicines, and ultimately achieve its goal of £33bn per year in sales by 2031.

She came to GSK from the role of regional president, Latin America, at EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany. Previously at EMD Serono, she was SVP of global oncology. Prior to this, she spent thirteen years at Pfizer leading various business units around the world including oncology and vaccines.

Martinez-Davis earned her undergraduate degree from Saint Louis University and a Master Direccion Comercial y Marketing from the Instituto de Empresa.